Skip to main content
. Author manuscript; available in PMC: 2020 Sep 15.
Published in final edited form as: Clin Cancer Res. 2019 Dec 12;26(6):1338–1348. doi: 10.1158/1078-0432.CCR-19-1728

Figure 1. Selinexor synergizes with GEM and nab-paclitaxel in PDAC cellular models.

Figure 1.

MiaPaCa-2 [A] or L3.6pl [B] cells growing in 96 well plates (5,000 cells/well) were exposed to vehicle, selinexor, GEM-nab-paclitaxel or selinexor-GEM-nab-paclitaxel for 72 hrs and standard MTT assay was performed. Isobologram analysis was performed and combination index (CI) was calculated using GraphPad Prism software. Data is representative of 3 independent experiments. MiaPaCa-2 [C] or L3.6pl [D] cells growing in 6 well plates (50,000 cells/well) for 24 hrs and exposed to selinexor (300 nM), GEM (90 nM), nab-paclitaxel (1.5 nM), selinexor+GEM, selinexor+nab-paclitaxel, GEM+nab-paclitaxel or a triple combination of selinexor, GEM and nab-paclitexal for 72 hrs. The cells were trypsinized and collected. 1000 cells from each treatment group were reseeded in 100 mm petri dishes. Clonogenic assay was performed. The plates were photographed under a light microscope (Nikon). L3.6pl [E] or MiaPaCa-2 [F] cells were grown in 6 well plates in duplicate and exposed to different drugs (at doses mimicking clonogenic assay) for 72 hrs. At the end of the treatment period, cells were trypsinized and 10,000 cells were subjected to Annexin V FITC analysis (Biovision USA).